A Highly Potent SARS-CoV-2 Blocking Lectin Protein
Open Access
- 15 April 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 8 (7), 1253-1264
- https://doi.org/10.1021/acsinfecdis.2c00006
Abstract
The COVID-19 (coronavirus disease-19) pandemic affected more than 180 million people around the globe, causing more than five million deaths as of January 2022. SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the new coronavirus, has been identified as the primary cause of the infection. The number of vaccinated people is increasing; however, prophylactic drugs are highly demanded to ensure secure social contact. A number of drug molecules have been repurposed to fight against SARS-CoV-2, and some of them have been proven to be effective in preventing hospitalization or ICU admissions. Here, we demonstrated griffithsin (GRFT), a lectin protein, to block the entry of SARS-CoV-2 and its variants, Delta and Omicron, into the Vero E6 cell lines and IFNAR(-/-) mouse models by attaching to the spike protein of SARS-CoV-2. Given the current mutation frequency of SARS-CoV-2, we believe that GRFT protein-based drugs will have a high impact in preventing the transmission of both the Wuhan strain as well as any other emerging variants, including Delta and Omicron variants, causing the high-speed spread of COVID-19.Keywords
Funding Information
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
- Ministry of Industry, and Technology of Turkey
This publication has 62 references indexed in Scilit:
- Impact of the griffithsin anti-HIV microbicide and placebo gels on the rectal mucosal proteome and microbiome in non-human primatesScientific Reports, 2018
- Inactivation of Middle East respiratory syndrome‐coronavirus in human plasma using amotosalen and ultraviolet A lightTransfusion, 2017
- Non-encapsulation approach for high-performance Li–S batteries through controlled nucleation and growthNature Energy, 2017
- Middle East respiratory syndrome coronavirus infection is inhibited by griffithsinAntiviral Research, 2016
- Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human PapillomavirusAntimicrobial Agents and Chemotherapy, 2015
- Binding of the Mannose-Specific Lectin, Griffithsin, to HIV-1 gp120 Exposes the CD4-Binding SiteJournal of Virology, 2011
- Investigation of Griffithsin's Interactions with Human Cells Confirms Its Outstanding Safety and Efficacy Profile as a Microbicide CandidatePLOS ONE, 2011
- Broad-Spectrum In Vitro Activity and In Vivo Efficacy of the Antiviral Protein Griffithsin against Emerging Viruses of the Family CoronaviridaeJournal of Virology, 2010
- Domain-Swapped Structure of the Potent Antiviral Protein Griffithsin and Its Mode of Carbohydrate BindingStructure, 2006
- Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor cultureProtein Expression and Purification, 2006